158 related articles for article (PubMed ID: 24255602)
1. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Boeru G; Milanov I; De Robertis F; Kozubski W; Lang M; Rojas-Farreras S; Tomlinson M
Med Devices (Auckl); 2013; 6():175-84. PubMed ID: 24255602
[TBL] [Abstract][Full Text] [Related]
2. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
3. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort
Thakur K; Manuel L; Tomlinson M
Pragmat Obs Res; 2013; 4():19-26. PubMed ID: 27774021
[TBL] [Abstract][Full Text] [Related]
4. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
5. Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA.
Verdun di Cantogno E; Tomlinson M; Manuel L; Thakur K
Pragmat Obs Res; 2014; 5():53-64. PubMed ID: 27774029
[TBL] [Abstract][Full Text] [Related]
6. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
[TBL] [Abstract][Full Text] [Related]
7. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
[TBL] [Abstract][Full Text] [Related]
8. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
Limmroth V; Bayer-Gersmann K; Mueller C; Schürks M
JMIR Form Res; 2022 Mar; 6(3):e31972. PubMed ID: 35285806
[TBL] [Abstract][Full Text] [Related]
9. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
[TBL] [Abstract][Full Text] [Related]
10. BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT
Patti F; Martínez Ginés ML; Norenberg C; Duarte Caron F
Patient Prefer Adherence; 2020; 14():771-779. PubMed ID: 32425509
[TBL] [Abstract][Full Text] [Related]
11. Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
Barone DA; Singer BA; Merkov L; Rametta M; Suarez G
Neurol Ther; 2016 Dec; 5(2):155-167. PubMed ID: 27277705
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT
Köhler W; Bayer-Gersmann K; Neußer T; Schürks M; Ziemssen T
Front Neurol; 2021; 12():643126. PubMed ID: 33716945
[No Abstract] [Full Text] [Related]
13. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
14. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
[TBL] [Abstract][Full Text] [Related]
15. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
[TBL] [Abstract][Full Text] [Related]
16. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Ziemssen T; Sylvester L; Rametta M; Ross AP
Neurol Ther; 2015 Dec; 4(2):125-36. PubMed ID: 26662362
[TBL] [Abstract][Full Text] [Related]
17. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
18. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b.
Weller I; Saake A; Schreiner T; Vogelreuter J; Petroff N
Patient Prefer Adherence; 2015; 9():951-9. PubMed ID: 26185425
[TBL] [Abstract][Full Text] [Related]
19. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
